Skip to main content
Premium Trial:

Request an Annual Quote

Aventis Accepts $65.3 Billion Sanofi Takeover Bid; Deal Would Create World s 3rd Biggest Pharma

NEW YORK, April 26 (GenomeWeb News) - After having previously put up heavy resistance to a hostile takeover bid by French drug maker Sanofi-Synthelabo, Aventis said yesterday that it is recommending its shareholders accept the deal in light of improved terms.

 

In January, Sanofi offered roughly $60 billion to buy Aventis, which rejected the deal as offering "inferior value" to shareholders. This week, however, Aventis said that it has accepted a sweetened offer worth about $65.3 billion from Sanofi.

 

If accepted by Aventis' shareholders, the merger will create the world's third largest drugs firm behind number one Pfizer and number two GlaxoSmithKline - Aventis generated about $20 billion in net sales last year, while spending roughly $3.4 billion on research and development; Sanofi had sales of about $9.5 billion in 2003, and spent $1.5 billion on R&D.

 

The two companies also have numerous arrangements with genomics, informatics, and microarray firms, including Ardais, Affymetrix, Ingenuity, Serenex, and Pharsight. Aventis is also developing an antisense-based cancer drug with Genta.

 

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.